Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer

NCT ID: NCT00983268

Last Updated: 2015-06-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 21 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-10-31
• Study Completion Date: 2013-02-28

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells. Giving capecitabine and vorinostat together with radiation therapy may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat when given together with capecitabine and radiation therapy in treating patients with nonmetastatic pancreatic cancer.

Detailed Description

OBJECTIVES:

Primary

• Determine the maximum tolerated dose of vorinostat when given in combination with capecitabine and high-dose hypofractionated radiotherapy in patients with nonmetastatic pancreatic cancer.

Secondary

• Determine the safety and side effect profile of this regimen in these patients.
• Determine the response rate in patients treated with this regimen.

Correlative

• Compare pre- and post-treatment whole-cell HDAC-activity levels in peripheral blood mononuclear cell samples.
• Assess chromatin structure and DNA damage in surgical tumor tissue samples.
• Assess proliferation and apoptosis by in vivo imaging.

OUTLINE: This is a dose-escalation study of vorinostat.

Patients receive oral capecitabine twice daily and undergo high-dose hypofractionated radiotherapy once daily on days 1-5 and 8-12. Patients also receive oral vorinostat once daily on days 1-5, 8-12, 15-19, and 22-26 in the absence of disease progression or unacceptable toxicity.

Patients are evaluated for surgery within 6 weeks after completion of chemoradiotherapy. Patients with resectable disease proceed to surgery. Patients with unresectable disease may receive oral vorinostat once daily and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Blood samples are collected periodically for correlative laboratory studies. Patients also undergo diffusion-weighted MRI for analysis of in vivo tumor cellularity.

After completion of study therapy, patients are followed up periodically for 5 years.

Conditions

Pancreatic Cancer; Periampullary Adenocarcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment Arm

Group Type: EXPERIMENTAL

capecitabine

Intervention Type: DRUG

1000 mg taken by mouth on the days of radiation only.

vorinostat

Intervention Type: DRUG

Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses:

• Vorinostat,at 100 mg
• Vorinostat,at 200 mg
• Vorinostat, at 300 mg
• Vorinostat, at 400 mg

Radiotherapy

Intervention Type: RADIATION

High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.

Surgery to remove tumor

Intervention Type: PROCEDURE

Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.

Interventions

capecitabine

1000 mg taken by mouth on the days of radiation only.

Intervention Type: DRUG

vorinostat

Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses:

• Vorinostat,at 100 mg
• Vorinostat,at 200 mg
• Vorinostat, at 300 mg
• Vorinostat, at 400 mg

Intervention Type: DRUG

Radiotherapy

High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.

Intervention Type: RADIATION

Surgery to remove tumor

Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Patient must have histologically confirmed pancreatic or periampullary cancer.
• Patient must be > 18 years of age.
• Patient may be resectable, borderline resectable, or unresectable but locally advanced as determined by radiographic examination and consultation with a surgical oncologist.
• Patient must have Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.
• Female patients of childbearing potential must be willing to use birth control. The 2 birth control methods can be either 2 barrier methods or a barrier method plus a hormonal method to prevent pregnancy, used throughout the study starting with visit 1. The following are considered adequate barrier methods of contraception: diaphragm, condom (by the partner) or sponge. Other methods of contraception such as copper intrauterine device or spermicide may be used. Appropriate hormonal contraceptives will include any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents).Female patient of childbearing potential has a negative serum pregnancy test β-hCG within 7 days prior to receiving the first dose of vorinostat.
• Male patients agree to use an adequate method of contraception for the duration of the study.
• Patient has a life expectancy of at least 12 weeks
• Patient must have adequate organ function as indicated by the following laboratory values:
• Absolute neutrophil count (ANC) ≥1,500 /mcL
• Platelets ≥100,000 / mcL Hemoglobin ≥ 9 g/dL
• Coagulation
• Prothrombin Time or INR ≤1.5x upper limit of normal (ULN) unless receiving therapeutic anticoagulation
• Partial thromboplastin time (PTT) ≤1.2 times the ULN unless the patient is receiving therapeutic anticoagulation.
• K levels - Normal limits
• Mg levels - Normal limits
• Calculated creatinine *clearance ≥20 mL/min
• Serum total bilirubin ≤ 1.5 X ULN
• AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN
• Alkaline Phosphatase ≤ 2.5 X ULN

• Creatinine clearance should be calculated per institutional standard.
• Patient must be capable of understanding and complying with the study protocol and able to give informed consent.
• Measurable disease is not an eligibility requirement.

Exclusion Criteria

• Prior chemotherapy for pancreatic or periampullary cancer.
• Prior radiation to any area within the planned radiation field. All patients with history of prior radiation to any area must be approved by PI.
• Evidence of distant metastases on imaging.
• History of hypersensitivity to fluoropyrimidines or HDACs.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

National Comprehensive Cancer Network

NETWORK

Sponsor Role: collaborator

Vanderbilt-Ingram Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Emily Chan, MD, PhD

Assistant Professor of Medicine; Medical Oncologist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Emily Chan, M.D, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Vanderbilt-Ingram Cancer Center

Locations

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States

Countries

United States

Related Links

http://www.vicc.org/ct/

Vanderbilt-Ingram Cancer Center, Find a Clinical Trial

Other Identifiers

P30CA068485

Identifier Type: NIH

Identifier Source: secondary_id

View Link

VU-VICC-GI-0934

Identifier Type: -

Identifier Source: secondary_id

IRB# 090791

Identifier Type: -

Identifier Source: secondary_id

NCCN-M02

Identifier Type: -

Identifier Source: secondary_id

VICC GI 0934

Identifier Type: -

Identifier Source: org_study_id